Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunological proof-of-concept following treatment with tolerance-inducing cell products in patients with autoimmune diseases or receiving organ transplantation: A systematic review and meta-analysis of clinical trials.
Willekens B, Wens I, Wouters K, Cras P, Cools N. Willekens B, et al. Among authors: wens i. Autoimmun Rev. 2021 Aug;20(8):102873. doi: 10.1016/j.autrev.2021.102873. Epub 2021 Jun 11. Autoimmun Rev. 2021. PMID: 34119672 Free article. Review.
Does multiple sclerosis affect glucose tolerance?
Wens I, Dalgas U, Deckx N, Cools N, Eijnde BO. Wens I, et al. Mult Scler. 2014 Aug;20(9):1273-6. doi: 10.1177/1352458513515957. Epub 2013 Dec 17. Mult Scler. 2014. PMID: 24347183
12 Weeks of Combined Endurance and Resistance Training Reduces Innate Markers of Inflammation in a Randomized Controlled Clinical Trial in Patients with Multiple Sclerosis.
Deckx N, Wens I, Nuyts AH, Hens N, De Winter BY, Koppen G, Goossens H, Van Damme P, Berneman ZN, Eijnde BO, Cools N. Deckx N, et al. Among authors: wens i. Mediators Inflamm. 2016;2016:6789276. doi: 10.1155/2016/6789276. Epub 2016 Jan 20. Mediators Inflamm. 2016. PMID: 26903712 Free PMC article. Clinical Trial.
Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA.
Derdelinckx J, Mansilla MJ, De Laere M, Lee WP, Navarro-Barriuso J, Wens I, Nkansah I, Daans J, De Reu H, Jolanta Keliris A, Van Audekerke J, Vanreusel V, Pieters Z, Van der Linden A, Verhoye M, Molenberghs G, Hens N, Goossens H, Willekens B, Cras P, Ponsaerts P, Berneman ZN, Martínez-Cáceres EM, Cools N. Derdelinckx J, et al. Among authors: wens i. J Neuroinflammation. 2019 Aug 15;16(1):167. doi: 10.1186/s12974-019-1541-1. J Neuroinflammation. 2019. PMID: 31416452 Free PMC article.
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.
Willekens B, Presas-Rodríguez S, Mansilla MJ, Derdelinckx J, Lee WP, Nijs G, De Laere M, Wens I, Cras P, Parizel P, Van Hecke W, Ribbens A, Billiet T, Adams G, Couttenye MM, Navarro-Barriuso J, Teniente-Serra A, Quirant-Sánchez B, Lopez-Diaz de Cerio A, Inogés S, Prosper F, Kip A, Verheij H, Gross CC, Wiendl H, Van Ham MS, Ten Brinke A, Barriocanal AM, Massuet-Vilamajó A, Hens N, Berneman Z, Martínez-Cáceres E, Cools N, Ramo-Tello C; RESTORE consortium. Willekens B, et al. Among authors: wens i. BMJ Open. 2019 Sep 9;9(9):e030309. doi: 10.1136/bmjopen-2019-030309. BMJ Open. 2019. PMID: 31501122 Free PMC article.
50 results